http://austinpublishinggroup.com/austin-hepatology/fulltext/hepatology-v1-id1001.php
Mannaerts et al. recently reported that the
effect or protein, Yap of the Hippo pathway regulates liver fibrosis by
controlling the activation of hepatic stellate cells. The authors elegantly
demonstrate that Yap activation induces fibrotic phenotype using in vitro as
well as in vivo models. Besides contributing to liver failure, cirrhosis an
advanced stage of fibrosis is known to be a major underlying disease of primary
liver cancer, Hepatocellular Carcinoma (HCC). Thus experimental
characterization of Yap’s role in fibrogenesis is clinically relevant due to
the necessity for a viable antifibrotic therapy.
Emerging data show that Yap and hippo pathway
in general are involved in liver enlargement and the associated clonal
expansion of HCC. Yet, detailed mechanistic insights on the molecular
regulation of fibrogenesis by Yap remain unclear. Recent reports document that
energy producing pathways are altered in early/late cirrhotic stages and
selective deregulation/ disruption of such metabolic alteration block fibrotic
phenotype in vitro and in vivo.Thus, accumulating data indicate that metabolic
alteration is indispensable for the progression of fibrosis/ cirrhosis.
Corroborating this, Yap and Hippo signaling mechanism have also been found to be
regulated by energy stress. Importantly, glucose-mediated energy homeostasis
has been shown to regulate Hippo pathway which in turn affects pro-glycolytic
function of Yap. Multiple lines of evidence have established that
metabolism-related oxidative stress is a major facilitator of fibrosis.
Intriguingly, evidences also show that Yap- Hippo pathway is affected by
oxidative stress. Taken together, it is thus far evident that cellular stress
contributes for fibrogenesis and Yap-Hippo pathway is affected by such cellular
stress during fibrogenesis. Future investigations focusing on molecular
intricacies of Yap regulation by metabolic stress will be critical and relevant
to identify potential therapeutic target (s) and development of any viable and
translatable strategy to treat liver fibrosis/cirrhosis.
No comments:
Post a Comment